| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Cash | 5.97 | 6.37 | 1.48 | 0.69 |
| Receivables | 15.41 | 36.18 | 0.55 | 0.04 |
| Inventory | 0.12 | 0.12 | 0.03 | — |
| Other | 3.06 | 2.69 | — | — |
| 25.76 | 46.32 | 4.08 | 0.76 |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Payables | 5.24 | 4.43 | 6.58 | 13.12 |
| ST’ Debt | 5.89 | 4.50 | 3.32 | 8.22 |
| Other | 0.06 | 0.07 | — | — |
| 15.37 | 15.91 | 16.41 | 26.92 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’24 | 0.14 | 0.25 | 0.35 | 0.30 |
1.04
|
| ’23 | 0.14 | 0.11 | 0.11 | 0.17 |
0.53
|
| ’22 | 7.21 | 7.20 | 7.99 | 13.62 |
36.03
|
| ’21 | 9.39 | 10.55 | 8.68 | 6.89 |
35.50
|
| ’20 | 1.88 | 1.75 | 1.73 | 2.30 |
7.65
|
| ’19 | 0.42 | 1.13 | 1.23 | 1.12 |
3.90
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’24 | (4.44) | (5.91) | (4.63) | (2.10) |
(17.08)
|
| ’23 | (7.24) | (5.91) | (1.18) | (0.50) |
(14.84)
|
| ’22 | (2.79) | (6.41) | (4.96) | (10.76) |
(24.92)
|
| ’21 | (4.55) | (11.50) | (8.35) | (2.46) |
(26.87)
|
| ’20 | (13.69) | (9.14) | (9.98) | (45.23) |
(78.05)
|
| ’19 | (4.51) | (3.66) | (2.35) | (2.71) |
(13.22)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’24 | (4.64) | (5.91) | (4.69) | (2.10) |
(17.34)
|
| ’23 | (8.52) | (6.42) | (1.48) | (0.50) |
(16.93)
|
| ’22 | (3.69) | (9.80) | (7.57) | (16.03) |
(37.09)
|
| ’21 | (5.08) | (12.51) | (10.17) | (6.97) |
(34.73)
|
| ’20 | (14.39) | (9.41) | (10.30) | (45.46) |
(79.56)
|
| ’19 | (5.47) | (5.42) | (5.67) | (8.71) |
(25.27)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’24 | (2.90) | (2.30) | (1.93) | (4.38) |
(11.44)
|
| ’23 | (1.70) | (1.50) | (4.30) | — |
(19.10)
|
| ’22 | (1.60) | (2.20) | (0.50) | (1.60) |
(5.90)
|
| ’21 | (0.10) | 1.10 | 4.20 | (2.00) |
(7.40)
|
| ’20 | 42.30 | 9.50 | (1.10) | (2.14) |
2.90
|
| ’19 | 5.50 | 3.60 | 4.40 | (4.20) |
(17.70)
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 11.30 | 3.84 | 0.87 | — | — | — |
Low Price
|
| — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 40.40 | 26.40 | 10.80 | — | — | — |
High Price
|
| — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 167 | 146 | 77 | — | — | — |
Employees
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.22 | 0.00 | 0.01 | — | — | — |
Revenue/Emp
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 36.03 | 0.53 | 1.04 | — | — | — |
Revenue
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 85.75% | (1,080.19%) | (86.28%) | — | — | — |
Gross Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.96) | (64.44) | (48.92) | — | — | — |
EBT
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.20%) | (12,159.43%) | (4,726.18%) | — | — | — |
EBT Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.17) | (64.92) | (49.01) | — | — | — |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.98 | 1.56 | 2.09 | — | — | — |
Depreciation
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.35 | 0.18 | 0.25 | — | — | — |
Revenue/Sh
|
| — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | (5.90) | (19.10) | (11.44) | — | — | — |
Earnings/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.93) | (5.11) | (4.06) | — | — | — |
Cash Flow/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.85) | (0.72) | (0.06) | — | — | — |
Capex/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.78) | (5.84) | (4.12) | — | — | — |
Free CF/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.58 | (7.23) | (8.91) | — | — | — |
Book Value/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.51 | 2.90 | 4.21 | — | — | — |
Shares
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.37 | 26.93 | 7.69 | — | — | — |
PS Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.69 | 0.00 | 0.00 | — | — | — |
PB Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.69 | 66.20 | 23.15 | — | — | — |
EV/Sales
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.64) | (2.07) | (1.38) | — | — | — |
EV/FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (24.92) | (14.84) | (17.08) | — | — | — |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.17) | (2.10) | (0.26) | — | — | — |
Capex
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (37.09) | (16.93) | (17.34) | — | — | — |
FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 30.41 | (12.33) | (26.16) | — | — | — |
Working Cap'
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.94 | 22.29 | 16.69 | — | — | — |
Total Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.57 | 20.81 | 16.01 | — | — | — |
Net Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 29.07 | (20.98) | (37.53) | — | — | — |
Sh' Equity
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (19.75%) | (104.97%) | (605.73%) | — | — | — |
ROA
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (15.55%) | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (43.98%) | (1,368.97%) | 164.62% | — | — | — |
ROE
|
Orgenesis Inc. (ORGS), a biotech innovator in point-of-care cell therapies and gene editing, has plummeted from $168 peaks in 2018 to penny-stock levels amid revenue crashes, endless losses, and brutal share dilution—shares exploding from 2.5 million to 30.5 million. Yet analysts are wildly bullish, unanimously forecasting over 10,900% upside, betting on a dramatic turnaround fueled by partnerships like Thermo Fisher, FDA designations, and expansions in Asia.
Revenue soared to $36 million in 2022 before imploding 98.5% to $0.53 million in 2023, with profitability elusive—EPS hit -19.1 last year amid negative margins and cash burn. The balance sheet shows negative equity and liquidity strains, but 2024 projections dazzle: $70.3 million revenue (13,000%+ rebound), $16.2 million profits, and positive cash flow from scaling GMP facilities and CAR-T launches.
This high-risk biotech play hinges on execution amid dilution risks, competition, and funding woes, but its decentralized model could tap a $20B+ cell therapy market. With forward PE at 1x and peers in the rearview, ORGS screams distressed turnaround—or total bust. Dive into the full analysis for the numbers that could make or break it.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.